• Dr.Raghavendra Rao M.V Scientist-Emeritus,Apollo Institute of Medical Sciences and Research, Jubilee Hills, Hyderabad, T S, India
  • Dr. Mahendra Kumar Verma Assistant Professor, American University School of Medicine, Aruba, Netherlands Antilles,
  • Dr.M. M. Karindas Professor, Department of Oncology, world Academy of Medical sciences, Netherlands
  • Dr.Ilie Vasiliev Professor, Department of Internal medicine, world Academy of Medical sciences, Netherlands
  • Dr.Dilip Mathai Distinguished Professor and Advisor ,The Apollo University , Chittoor ,Andhra Pradesh India


Gain-of-Function, mice, and guinea pigs, immunogenicity, Dual-use research of concern (DURC)


Gain-of-function experiments may help medical researchers to test scientific theories, develop new technologies and find treatments for infectious diseases. When the original SARS-CoV outbreak occurred in 2003, scientists developed a method to study the virus in the laboratory, by growing the virus in mice. This endeavour showed a model for researching the virus and testing potential vaccines and treatments. Inadequate and insufficient research on viruses will authorize unaware of future pandemics. But too little consciousness of security threats will multiply the hazards that an experiment virus may escape a lab through an accident and cause an outbreak of its own. A virus generated in the lab by genetically modified its gene products, altering an organism, and if accidentally released, could result in millions of deaths.

Gain-of-Function research is followed in scientific studies to cautiously understand the possibility of the emergence of infectious viruses in nature. Gain-of-Function experiments include engineering in the lab genetic alterations that simulate an increase in virulence. The organism modified this way is tested on laboratory animals like ferrets, mice, and guinea pigs. These tests provide insight that is utilized to develop vaccines, test out new antivirals, understand the host-immune response, and comprehend the disease-causing ability of the virus. In this way, we can remain a step ahead of viral evolution by developing suitable medical countermeasures. Gain-of-function research is the serial passaging of microorganisms to increase transmissibility, virulence, immunogenicity, and host tropism. 


I. Miller S, Selgelid MJ. Ethical and philosophical consideration of the dual-use dilemma in the biological sciences. Dordrecht, NE: Springer; 2008.

II. National Research Council (NRC) and Institute of Medicine (IOM) Potential risks and benefits of gain-of-function research: Summary of a workshop. Washington, DC: National Academies Press; 2015

III. Jackson RJ, Ramsay AJ, Christensen CD, Beaton S, Hall DF, Ramshaw IA. Expression of mouse interleukin-4 by a recombinant ectromelia virus overcomes genetic resistance to mousepox. Journal of Virology. 2001;75:1205–1210

IV. Osterhaus, A. D.; Rimmelzwaan, G. F.; Martina, B. E.; Bestebroer, T. M.; Fouchier, R. A. (2000-05-12). "Influenza B virus in seals". Science. 288 (5468): 1051–1053. Bibcode:2000Sci...288.1051Retrieved 25 May 2021.

V. Gain-of-Function Research: Background and Alternatives. National Academies Press (US). 2015-04-13. Retrieved 25 May 2021

VI. Imperiale, Michael J.; Howard, Don; Casadevall, Arturo (28 August 2018). The Silver Lining in Gain-of-Function Experiments with Pathogens of Pandemic Potential. Influenza Virus. Methods in Molecular Biology. Vol. 1836. pp. 575–587.

VII. Selgelid, Michael J. (2016-07-06). "Gain-of-Function Research: Ethical Analysis". Science and Engineering Ethics. 22 (4): 923–964.

VIII. "Recommended Policy Guidance for Departmental Development of Review Mechanisms for Potential Pandemic Pathogen Care and Oversight (P3CO)" (PDF). Department of Health and Human Services. Office of the Assistant Secretary for Preparedness and Response. 9 January 2017.

IX. Sander Herfst , Eefje J A Schrauwen, Martin Linster, Salin Chutinimitkul, Airborne transmission of influenza A/H5N1 virus between ferrets,Science, 2012 Jun 22;336(6088):1534-41.

X. Jeong Seok Lee , Eui-Cheol Shin,The type I interferon response in COVID-19: implications for treatment,Nat Rev Immunol,2020 Oct;20(10):585-586.

XI. Jeong Seok Lee , Eui-Cheol Shin,The type I interferon response in COVID-19: implications for treatment,. Nat Rev Immunol. 2020 Oct;20(10):585-586.doi: 10.1038/s41577-020-00429-3

XII. Kun Li , Zhuo Li , Christine Wohlford-Lenane , David K Meyerholz , Rudragouda Channappanavar , Dong An , Stanley Perlman , Paul B McCray Jr Biao He Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection,2020 Apr 7;11(2):e00554-20.

XIII. Dong An; Kun Li; Dawne K. Rowe; Maria Cristina Huertas Diaz; Emily F. Griffin; Ashley C. Beavis; Scott K. Johnson; Ian Padykula; Cheryl A. Jones; Kelsey Briggs et al.Protection of K18-hACE2 mice and ferrets against SARS-CoV-2 challenge by a single-dose mucosal immunization with a parainfluenza virus 5–based COVID-19 vaccine,Science Advances,2021-07-02

XIV. S. I. Phan, Z. Chen, P. Xu, Z. Li, X. Gao, S. L. Foster, M. N. Teng, R. A. Tripp, K. Sakamoto, B. He, A respiratory syncytial virus (RSV) vaccine based on parainfluenza virus 5 (PIV5). Vaccine 32, 3050–3057 (2014).

XV. S. I. Phan, J. R. Zengel, H. Wei, Z. Li, D. Wang, B. He, Parainfluenza virus 5 expressing wild-type or prefusion respiratory syncytial virus (RSV) fusion protein protects mice and cotton rats from RSV challenge. J. Virol,91, e00560-17 (2017).

XVI. A. J. Mooney, Z. Li, J. D. Gabbard, B. He, S. M. Tompkins, Recombinant parainfluenza virus 5 vaccine encoding the influenza virus hemagglutinin protects against H5N1 highly pathogenic avian influenza virus infection following intranasal or intramuscular vaccination of BALB/c mice. J. Virol. 87, 363–371 (2013)

XVII. E. J. Kontor, R. J. Wegrzyn, R. A. Goodnow, Canine infectious tracheobronchitis: Effects of an intranasal live canine parainfluenza-Bordetella bronchiseptica vaccine on viral shedding and clinical tracheobronchitis (kennel cough). Am. J. Vet. Res. 42, 1694–1698 (1981).

XVIII. Z. Chen, P. Xu, G. W. Salyards, S. B. Harvey, B. Rada, Z. F. Fu, B. He, Evaluating a parainfluenza virus 5-based vaccine in a host with pre-existing immunity against parainfluenza virus 5. PLOS ONE 7, e50144 (2012).

XIX. D. Wang, S. Phan, D. J. Di Stefano, M. P. Citron, C. L. Callahan, L. Indrawati, S. A. Dubey, G. J. Heidecker, D. Govindarajan, X. Liang, B. He, A. S. Espeseth, A single-dose recombinant parainfluenza virus 5-vectored vaccine expressing respiratory syncytial virus (RSV) F or G protein protected cotton rats and african green monkeys from RSV challenge. J. Virol. 91, e00066-17 (2017).

XX. J. Zheng, L.-Y. R. Wong, K. Li, A. K. Verma, M. E. Ortiz, C. Wohlford-Lenane, M. R. Leidinger, C. M. Knudson, D. K. Meyerholz, P. B. McCray Jr., S. Perlman, COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice. Nature 589, 603 607 (2002)

XXI. . michael J. Selgelid,Gain-of-Function Research: Ethical Analysis,Sci Eng Ethics. 2016; 22(4): 923–964.2016 Aug 8.

XXII. Bloomberg,The last–and only–foreign scientist in the Wuhan lab speaks outJune 28, 2021 12:29 IST

XXIII. Express Web Desk,Covid-19 was a ‘man-made’ virus, claims scientist who worked at the Wuhan lab,TheIndianExpress,December 6, 2022 14:30 IST


XXV. Jacob Koshy,January 28, 2022 05:17 pm | Updated January 29, 2022 12:04 pm IST - Beijing, 38339161.ece

XXVI. 26.



Additional Files



How to Cite

Dr.Raghavendra Rao M.V, Dr. Mahendra Kumar Verma, Dr.M. M. Karindas, Dr.Ilie Vasiliev, & Dr.Dilip Mathai. (2023). IS GAIN-OF-FUNCTION RESEARCH UNLOCKING THE SECRETS OF HIDDEN DANGEROUS VIRUSES?. International Education and Research Journal (IERJ), 9(1). Retrieved from

Most read articles by the same author(s)